entertainment -WSS

entertainment

author：leisure time 2025-09-29 19:06:26 - browse：1

DENVER — He could have been a rock star, a religious icon, the way ecstatic applause from thousands of attendees greeted the man dressed in a crisp, all-white suit as he strode onto a backlit stage. He was neither. This was Rick Doblin, the founder and evangelist of a movement to legalize psychedelic MDMA and bring the drug into mainstream medicine.

The scene in a Denver conference hall last week was a world away from the first conference Multidisciplinary Association for Psychedelic Studies (MAPS) held in 1990, when Doblin spoke alongside Timothy Leary — the ex-Harvard professor who popularized the phrase “turn on, tune in, and drop out.” That was just a few years after MDMA, also known as ecstasy, was criminalized, deemed a Schedule 1 drug “of no medical use.”

Now, as MAPS nears its goal of winning Food and Drug Administration approval for MDMA as a treatment for post-traumatic stress disorder, the perpetually smiling and energetic Doblin is basking in the adoration from both legions of “psychonauts” and unlikely yet powerful allies. “I literally love Rick Doblin,” the conservative Republican and former Texas governor Rick Perry told the audience in Denver.

It was a seemingly triumphant occasion. But even as Doblin is in sniffing distance of his lifelong quest, his once counter-cultural organization is grappling with the pressures of having to operate in the capitalist pharmaceutical sphere. MAPS was founded in 1986 as a nonprofit with deep-seated ideals. Doblin developed an “anti-patent” strategy, putting discoveries in the public domain so they couldn’t be claimed as intellectual property. He raised money to fund clinical trials of MDMA from like-minded wealthy donors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Abortion policy in the spotlight at Republican debate

WSS

Why some fertility treatments produce more boy babies

Wegovy improves function in certain heart failure patients

Listen: Vivek Ramaswamy's star turn & leaky drug data

Ozempic cut risk of death in diabetes patients with chronic kidney disease

People can get long Covid without testing positive for virus: Study

Should insurance cover cosmetic surgery?

hotspot

entertainment

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

Hospital at home shows how to bring innovation to health care

BioMarin wins approval for gene therapy to treat hemophilia A

Decentralized clinical trials need collaboration to achieve wider use

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Some medical students still think black patients feel less pain

Apple is now the first public company to be valued at $3 trillion

People can get long Covid without testing positive for virus: Study

Novavax promises a turnaround & Lilly roils the obesity market

New research sheds light on how often breast cancer is overdiagnosed

focus

Stroke rates rising, especially in working

Should insurance cover cosmetic surgery?

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Former Pear Therapeutics executives start new VC firm

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

J&J reports mixed data on next

explore

entertainment

entertainment

focus